

An Early Diagnosis Framework For Mild Cognitive Impairment And Alzheimer's Disease Using Multi-Model Classification

V Lavanya , M. Tech.,(Ph.D).,

Assistant professor

Department of Computer Science and Engineering,

Siddharth Institute of Engineering and Technology(Autonomous), Puttur, India.

lavanya.v432@gmail.com

Bojanapu Santhosh, 22F61A47D6

Department of Computer Science and Engineering with Specialization Artificial Intelligence and Data Science,

Siddharth Institute of Engineering and Technology(Autonomous), Puttur, India.

bsanthosh2793@gmail.com

G Sandhya, 22F61A47D3

Department of Computer Science and Engineering with Specialization Artificial Intelligence and Data Science,

Siddharth Institute of Engineering and Technology(Autonomous), Puttur, India.

sandhyagogineni43@gmail.com

Dugganapalli Siddartha Reddy,

22F61A47E7

Department of Computer Science and Engineering with Specialization Artificial Intelligence and Data Science,

Siddharth Institute of Engineering and Technology (Autonomous), Puttur, India.

reddysiddarth83@gmail.com

D Tulasi Prasad , 22F61A47G0

Department of Computer Science and Engineering with Specialization Artificial Intelligence and Data Science,

Siddharth Institute of Engineering and Technology(Autonomous), Puttur, India.

tulasiprasad2526@gmail.com

ABSTRACT

Early clinical intervention and accurate diagnosis of Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD) are prerequisites for effective disease management. The majority of

conventional diagnostic methods, such as clinical assessments and single-model machine learning approaches, rely on heterogeneous data and cognitive stage-specific symptoms. An early diagnosis framework for MCI and Alzheimer's disease is presented in this paper, utilizing multi-model classification. By integrating various machine learning models, the proposed system can exploit their shared strengths and enhance diagnostic precision. By integrating neuroimaging features, cognitive test scores, and clinical characteristics, the framework enhances the differentiation of healthy control, MCI, and AD classes. Experimental evidence supports the multi-model approach's superiority over individual classifiers in terms of accuracy, sensitivity, and generalization. By providing clinicians with a strong decision-support tool, the framework contributes to early detection of neurodegenerative disorders.

Keywords: Experimental, neurodegenerative, clinicians, sensitivity.

I INTRODUCTION

Mild Cognitive Impairment is commonly viewed as an intermediate stage between normal aging and Alzheimer's disease, often serving as early warning signs of progressive cognitive decline. To initiate therapeutic strategies that can decelerate the disease and prolong the patient's life, it is crucial to detect MCI early in the pathology and Alzheimer's disease.

Still, it is challenging to diagnose early on because of subtle differences in symptoms, high inter-subject variability, and similarities between normal aging and pathological decline. The diagnostic methods that have been traditionally employed rely on neuropsychological

assessments and clinician expertise, which can be subjective and time-consuming. Data-driven cognitive disorder diagnosis can now be made possible by machine learning, which has advanced to incorporate neuroimaging data, clinical information, and behavioral data.

Although single-model classifiers have shown some success, they often underestimate the full complexity of disease patterns because of model bias and insufficient feature representation. Several multi-model classification frameworks address these limitations by incorporating various learning algorithms to improve its robustness and accuracy. Such frameworks

use different decision boundaries, and complementary learning capabilities to allow generalization across heterogeneous datasets.

II. LITERATURE SURVEY

In [1], Clinical assessments and statistical analysis of cognitive test scores were the primary means of diagnosing Mild Cognitive Impairment and Alzheimer's disease in early studies. While they could identify the advanced stages of dementia, these methods were only effective in detecting early-stage dementia with limited accuracy. Due to the absence of objective biomarkers and reliance on clinician expertise, diagnoses were either delayed or inconsistent. Therefore, scientists started investigating computational methods to aid in early detection. The high inter-patient variability and overlapping symptoms between normal aging and MCI in early models led to the need for more robust data-driven diagnostic methods. However, these early model failures were still observed by some researchers.

In [2], Machine learning techniques were instrumental in improving the diagnosis of Alzheimer's disease, as they learned discriminative patterns from neuroimaging

and clinical data. Algorithms such as support vector machines, decision trees and k-nearest neighbors showed improvements in classification accuracy between healthy controls and Alzheimer's patients. However, the majority of these studies were based on single-model classifiers that were sensitive to feature selection and data imbalance. Often these limitations led to reduced generalization performance, especially when distinguishing Mild Cognitive Impairment from early Alzheimer's disease, which encouraged more intensive investigation into stronger multi-model learning strategies.

In [3], The advent of deep learning allowed for the automatic extraction of features from high-dimensional neuroimaging data, including MRI and PET scans. Significant improvements in performance were achieved by convolutional neural networks through their ability to capture intricate spatial patterns linked to neurodegeneration. The practical use of deep learning models in clinical settings is limited by the need for large labeled datasets and high computational resources. Moreover, the limited interpretability of deep learning techniques often makes it difficult for clinicians to have faith in and validate predictions. Researchers were encouraged

by these challenges to explore hybrid and ensemble methods that aimed to balance performance with interpretability.

In [4], Recently, ensemble and multi-model classification techniques have become a focus area due to their potential for improving diagnostic robustness. Ensemble methods are used to reduce individual model bias and variance, which can be achieved by combining multiple classifiers for better generalization. In studies involving ensemble learning for diagnosing Alzheimer's, accuracy and stability were found to be higher than single-model approaches. A wide range of datasets, including neuroimaging, cognitive, and clinical features, were made feasible by multi-model frameworks. These findings suggest that early diagnosis accuracy is improved and clinical decision-making can be more consistent by incorporating complementary learning models.

In [5], Mild Cognitive Impairment is a critical factor in the slow progression of Alzheimer's, as per recent research. Several multi-model classification frameworks have been suggested to account for subtle cognitive changes and enhance sensitivity during early stages. Various feature sets and

learning models are integrated in these approaches, which enable better discrimination between normal aging patterns, MCI, and Alzheimer's disease. Several studies have demonstrated that multi-model systems are more effective than traditional classifiers for early-stage diagnosis. Nonetheless, the challenges of achieving optimal model integration and scalability necessitate ongoing research. This is particularly challenging.

III. PROPOSED SYSTEM

A multi-model classification system has been proposed to aid in the early diagnosis of Mild Cognitive Impairment and Alzheimer's disease. The framework is intended to combine various types of patient data and harness the complementary capabilities of several machine learning classifiers to enhance diagnostic accuracy and robustness. The process of data acquisition involves the gathering of standardized datasets, including those for neuroimaging features, cognitive assessment scores, and clinical parameters. The comprehensive representation of cognitive health is based on these diverse data sources.

Consistency and quality are maintained through data preprocessing. The tasks encompass noise cancellation, normalization, missing data handling, and feature scaling. Cognitive state classification involves the use of feature selection techniques to identify the most discriminative attributes. Multiple classification models, including support vector machines, random forests, k-nearest neighbors (and more) and logistic regression are used to incorporate the processed data. The models learn about patterns linked to MCI, Alzheimer's disease, and healthy cognition on their own.

Multi-model integration is the core of the system. The framework aggregates predictions from all models using ensemble techniques like majority voting or weighted averaging, rather than solely depending on identifying the classifier that provides coverage. This integration reduces bias in the individual model and allows generalization across different patient profiles. Due to its ability to capture a wider range of disease traits, the ensemble decision is regarded as achieving more precise diagnosis.




Fig 1. System Architecture

It also provides flexibility, and the framework can be expanded to include

additional models or features as new data becomes available. Individuals are classified into normal control, MCI, or Alzheimer's

disease based on the diagnostic output. As a clinical decision-support tool, it has great potential to offer early diagnosis assistance with its combination of multiple models and data sources that are both robust and easily interpretable.

IV. RESULT AND DISCUSSION

Benchmark datasets for the proposed multi-model classification framework included neuroimaging, cognitive, and clinical features associated with MCI and Alzheimer's disease. The effectiveness of the multi-model approach was evaluated by comparing its performance to individual classifiers. The assessment measures comprised accuracy, precision, recall, F1-score, and class-wise sensitivity, with a focus on early-stage MCI detection.

The multi-model framework is proven to be more effective than single-Model classifiers in all metrics, according to experimental evidence. Compared to other methods, the ensemble approach was more accurate in reducing misclassification between MCI and early Alzheimer's disease—a frequent problem in cognitive disorder diagnosis. Improved recall values indicate the framework is more accurately identifying affected people, which reduces false negatives and supports early intervention.)

When dealing with unseen data, the results demonstrate greater robustness and generalization.

Moreover, Due to their sensitivity to feature distributions and dataset variability, individual classifiers' performance underwent variations over time. Conversely, the integrated multi-model framework sustained steady performance, indicating the value of combining complementary learning approaches. It worked well as an 'effectively sensitive and specific' framework in which there was reliable differentiation across cognitive stages. ". Feature diversity and model integration are considered to be significant factors in improving diagnostic outcomes, as discussed.

The framework's computational overhead is slightly higher due to training multiple models, but the performance gains make it justifiable in clinical settings. In summary, the outcomes demonstrate that multi-model classification is a highly effective method for diagnosing MCI and Alzheimer's disease

early in training compared to conventional single model methods.




Fig 2. Validation Accuracy vs Epochs

However, the accuracy of validation closely reflects training trend, and shows that strong

generalization is possible on unseen data. The use of an ensemble-based learning approach results in less overfitting.




Fig 3. Performance Comparison

A comparison between single classifiers and the multi-model framework is presented by the bar chart, which measures accuracy, precision, recall, and F1-score. The multi-

model approach yields superior results across all metrics. This demonstrates enhanced strength and diagnostic dependability.'




Fig 4. ROC Curve (Normal vs MCI vs Alzheimer's Disease)

All classes exhibit high true positive rates and low false positive values on the ROC curve. A considerable area under the curve demonstrates exceptional discriminative

aptitude.' This demonstrates the effectiveness of the multi-model classification framework for early diagnosis.

V. CONCLUSION

This article presented a framework for early diagnosis of Mild Cognitive Impairment and Alzheimer's disease, using multiple models. Several machine learning models are integrated into the framework to improve early-stage detection capability, diagnostic accuracy and robustness, while also handling heterogeneous patient data. Experimental evidence supports its potential as an effective clinical decision-support method, with benefits evident beyond individual classifiers.... The future work will involve utilizing multimodal data, explaining AI techniques, and conducting clinical validation in real-world scenarios.

REFERENCES

1. J. C. Morris, "The Clinical Dementia Rating," *Neurology*, 1993.
2. C. R. Jack et al., "The Alzheimer's Disease Neuroimaging Initiative," *Neurology*, 2010.
3. S. Klöppel et al., "Automatic classification of Alzheimer's disease," *Brain*, 2008.
4. D. Zhang et al., "Multimodal classification of Alzheimer's disease," *NeuroImage*, 2011.

5. H. Suk et al., “Deep learning for Alzheimer’s disease diagnosis,” *NeuroImage*, 2014.
6. R. Polikar, “Ensemble learning,” *Ensemble Machine Learning*, 2012.
7. L. Breiman, “Random forests,” *Machine Learning*, 2001.
8. C. Cortes and V. Vapnik, “Support-vector networks,” *Machine Learning*, 1995.
9. E. M. A. Hannan et al., “Machine learning for early AD detection,” *Journal of Biomedical Informatics*, 2020.
10. J. Liu et al., “Data-driven diagnosis of neurodegenerative diseases,” *Artificial Intelligence in Medicine*, 2021.